Comparison of Features and Outcomes Between HIV-negative Patients with Cryptococcus Gattii Meningitis and Cryptococcus Neoformans Meningitis in South China
Xiao-Hong Su,Wei-Peng Li,Jun-Yu Liu,Yi-Jie Wang,Jia Liu,Xiao-Feng Xu,Lu Yang,Han Xia,Ying Jiang,Fu-Hua Peng
DOI: https://doi.org/10.1111/myc.13491
2022-01-01
Mycoses
Abstract:Objectives The objective of this study is to compare the epidemiologic, clinical, laboratory, and imaging features, and outcomes in patients with Cryptococcus gattii meningitis (CGM) and Cryptococcus neoformans meningitis (CNM). Methods We performed a retrospective study of HIV-negative patients with CGM and CNM (2015-2021) distinguished by metagenomic next-generation sequencing in cerebrospinal fluid in South China. Results A total of 81 patients (17 CGM, 64 CNM) were enrolled (72.8% male, median age 49 years, range 21-77 years), and CGM patients were younger (median, 43 vs 53 years, p = .005). Of 17 CGM, VGI and VGII accounted for 70.6% and 29.4%, respectively. CGM patients had less underlying diseases (7/17 [41.2%] vs 48/64 [75%], p = .018) and focal neurologic deficit (3/17 [17.6%] vs 35/64 [54.7%], p = .022), had higher intracranial pressure (15/17 [88.2%] vs 25/64 [39.1%], p = .002), more meningeal enhancement (14/17 [82.4%] vs 32/64 [50%], p = .034), less parenchymal involvement (median, 1 vs 3, p = .018), more lung cryptococcomas (6/12 [50%] vs 6/47 [12.8%], p = .014), faster CSF fungal clearance (p = .004), less complications (median, 1 vs 3, p < .001), and more favourable outcomes (16/17 [94.1%] vs 41/64 [64.1%], p = .035). Conclusions This study demonstrated that species identification helps to guide therapy and predict outcomes.